DOCSLIB.ORG

Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD. 130DEG./7.5 L NC077K 8451.29 NECK METHA MOD. 130DEG/7.5 L-R NC079K 8400.06 NEEDLE HOLDER WEBSTER P0405 0 POLYP ETRAP 00711099 1202.32 SET CLEANING BRUSHES 0 TIDISHIELD FRAMES/LENS 9210A-100 0 #1613 VENTILATOR CIR 20.01 #1627 VENTILATOR CIR 21.39 #9 WINDOW ENVELOPE(LAB) 0 * 0 ** 3A ANDROSTANEDIOL GLUCURONIDE 345.81 ** ALKALINE PHOSPHATASE (FRAC) 70.66 ** ALKALINE PHOSPHATASE (FRAC) 99.51 ** CSF3R EXON 14/17 MUTATION 787.47 ** FCM EACH ADDITIONAL MARKER 19.76 ** FECAL ALPHA-1 ANTIRYPSIN 183.16 ** FLOW CYTO INTER/REPT 2 TO 8 MARKERS 115.37 ** TRICYCLIC ANTIDEPRESSANTS QNT UR 227.87 ** URINE PHOSPHORUS ASSAY 70.66 **% DELTA 2 HR 0 **% DELTA 4 HR 0 **% DELTA 6 HR 0 **(RI ANTIBODY WESTERN BLOT ATHENA 246.62 *****UR MICROSCOPIC ONLY 61.69 *****URINALYSIS CANCELLATION NOTICE 0 *****URINALYSIS,BIOCHEM REQUEST 0 *****URINALYSIS,BIOCHEM REQUEST 0 ****2HR URINE CREATININE 70.66 ****CHLAMYDIA PNEUMONIAE AB IGG 79.32 ****HLA TYPING FOR CELIAC DISEASE 0 ****PLATELET AB SERUM 250.95 ****PLATELET PHERESIS LEUKO RED IRRAD 2787.85 ****VMA-SERUM 294.23 ***ANAPLASMA AMP DNA PROBE 469.17 ***BLEEDING TIME 62.02 ***HLA-B27 DNA TYPING 0 ***HSV AB IGM 197.59 ***IGG SERUM 172.72 ***IMMUNOGLOBULIN IGA1 SUBCLASS 57.69 ***IMMUNOGLOBULIN IGA2 SUBCLASS 57.69 ***LYME ANTIGEN DETECTION ELISA 167.67 ***LYME IGM ANTIBODY 204.8 ***MOLD ALLERGEN SCREEN 109.61 ***PATHOLOGY GROSS ONLY 0 **1 HR INCUBATION MIX PROGRESSIVE 89.43 **11 DEOXYCORTISOL 187.49 **14-3-3 PROTEIN 184.83 **14-3-3 PROTEIN CSF, WESTERN BLOT 214.1 **2,3-DINOR-11 BETA-PROSTAGLANDIN F2A 295.74 **21-HYDROXYLASE ANTIBODIES 216.34 **24 URINE CALCIUM ASSAY 82.21 **2PN23 CHARGE ONLY 0 **5 GENE DELETION/DUPLICATION HHT 3892.66 **6 GENE DELETION/DUPLICATION PFSP 1495.67 **7 GENE SEQUENCING PFSP 1495.67 **AB SCREEN LIVER/KIDNEY 164.42 **AB TITER 164.42 **AB TITER LIVER/KIDNEY 164.42 **ABCD1 DNA SEQUENCING 1934.67 **AC-3 RBC LR 1289.36 **ACECYLOLNESTERASE RBC 105.29 **ACETONE 112.5 **ACETYL FENTANYL 252.39 **ACETYLCHOL RECEP BLOCKING AB 184.61 **ACETYLCHOLINESTERASE AF 152.88 **ACHR GANGLIONIC NEURONAL AB 184.61 **ACID FAST CONCENTRATION 92.3 **ACID FAST SMEAR(REF LAB) 73.56 **ACRIDINE ORANGE 73.56 **ACTINOMYCES CULTURE 281.25 **ACTIVATED PROTEIN C RESISTANCE 196.14 **ACYCLOVIR LEVEL 246.62 **ACYLCARNITINE QUANT 197.59 **ADALIMUMAB ACTIVITY 267.71 **ADALIMUMAB NEUTRALIZING AB 267.71 **ADDITIONAL STUDIES, STAINS 275.46 **ADENOVIRUS AG 118.26 **ADENOVIRUS ANTIBODY GROUP 79.32 **ADENOVIRUS ANTIGEN 183.16 **ADENOVIRUS CULTURE 356.24 **ADIPONECTIN 197.43 **ADMA/SDMA 246.62 **ADMARK AB42 ATHENA 715.35 **ADMARK APOE GENOTYPE ANALYSIS 816.09 **ADMARK PHOSPHO TAU-PROTEIN 715.35 **ADMARK PS1 DNA SEQUENSING, ATHENA 2487.87 **ADMARK TAU TOTAL 715.35 **ADRENAL ANTIBODIES TITER 164.42 **ADRENAL ANTIBODIES W/REFLEX 164.42 **AFB COMPLEX DNA PCR 470.18 **AFB SMEAR WITH CULTURE 117.09 **AFB SUSCEPTIBILITY CUSTOM PANEL 172.64 **AFP TUMOR MARKER, FLUID 229.32 **AFP-AMNIOTIC 229.32 **AGAR ELECTROPHORESIS 405.27 **AGNA-1 164.42 **AGPB CHARGE 2 0 **AIRE EVALUATION 1764.41 **ALBUMIN, CSF 50.32 **ALBUMIN, SERUM 56.32 **ALDACTONE LEVEL 187.49 **ALPHA 1 ACID GLYCOPROTEIN 206.24 **ALPHA 1 ANTITRYPSIN PHENOTYPE 263.68 **ALPHA 2 ANTIPLASMIN 115.37 **ALPHA 2 MACROGLOBULIN 155.76 **ALPHA FETOPROTEIN 259.72 **ALPHA GALACTOSIDASE 516.33 **ALPHA GALACTOSIDASE 558.29 **ALPHA SUBUNIT PITUITARY 177.41 **ALPHA-FETOPROTEIN PLEURAL FLUID 247.58 **ALPHA-GLOBIN GENE ANALYSIS 0 **ALPHA-GLOBIN GENE SEQUENCING 1045.63 **ALUMINUM LEVEL URINE 347.58 **AMG BY NEPHELOMETRY 213.45 **AMINO ACID SCREEN UR 147.1 **AMOXICILLIN LEVEL 187.49 **AMPHETAMINE CONFIRMATION 212.01 **AMPHETAMINE SCREEN 188.93 **AMPHETAMINE SCREEN 188.93 **AMPHIPHYSIN AB 164.42 **AMPHIPHYSIN WESTERN BLOT 246.62 **AMYLASE PANCREATIC ISOENZYMES 77.1 **AMYLOID B-PROTEIN 184.61 **ANA BODY FLUID 165.86 **ANACHOICE SPECIFIC AB CASCADE 165.86 **ANAPLASMA ABS PREVIOUS SPECIMEN 0 **ANAPLASMA HGE AB IGG 79.32 **ANAPLASMA HGE AB IGG 79.32 **ANAPLASMA HGE AB IGM 79.32 **ANAPLASMA HGE AB IGM 79.32 **ANCA AB DNASE PATTERN 395.17 **ANCA IBD 179.13 **ANCA IFA PATTERN 395.17 **ANTI 68 KD 212.01 **ANTI CBir1 ANTIBODY(PROMETHEUS) 177.41 **ANTI IGE IGG 175.95 **ANTI MI2 ANTIBODY 245.18 **ANTI SCL-100 ANTIBODY 245.18 **ANTI SRP ANTIBODY 245.18 **ANTIBIO SENS EACH 64.91 **ANTIBIO SENS PER ETEST ST 67.31 **ANTIBODY SCREEN 164.42 **ANTIBODY SCREEN (PEG3) 164.42 **ANTICARDIOLIPIN IGG 347.15 **ANTICARDIOLIPIN IGM 347.15 **ANTI-DNA AB SINGLE STRAND 165.86 **ANTI-GLIAL NUCLEAR AB, TYPE 1 229.32 **ANTI-PLATELET FACTOR 4 HEPARIN AB 177.41 **ANTITHROMBIN ANTIGEN, P 148.55 **APOLIPOPROTEIN 158.38 **APOLIPOPROTEIN A1 158.38 **APOLIPOPROTEIN B-100 158.38 **APRIPIPRAZOLE LEVEL 228.55 **APT TEST 105.29 **APTT REF LAB 171.62 **APTT-MIXING STUDY 82.21 **ARIPIPRAZOLE 227.87 **ARSENIC (HEAVY METAL) 179.18 **ARSENIC BL (HEAVY METAL) 179.18 **ARSENIC, HAIR 259.6 **ARYLSULFATASE A LEVEL 246.62 **ARYLSULFATASE A, LEUKOCYTES 199.03 **AS-1 PHER RBC LR 1289.36 **AS-1 RBC 1566.28 **AS-1 RBC LOW VOL 1566.28 **AS-1 RBC LR BAG 2 1289.36 **AS3 LR RED CELL PHERESIS 1566.28 **AS-3 RBC 1044.18 **AS-3 RBC 1044.18 **AS-3 RBC APHER BAG 2 2062.41 **AS-3 RBC APHER LR 2062.41 **AS-3 RBC APHER LR 2062.41 **AS-3 RBC LOW VOL 1566.28 **AS-3 RBC LOW VOL 1566.28 **AS-3 RBC LOW VOL 804.77 **AS-3 RBC LR 1289.36 **AS-3 RBC LR IRR 1266.29 **AS-3 RBC LR IRR 1266.29 **AS-3 RBC LR IRR BAG 1 1266.29 **AS-3 RBC LR IRR BAG 2 1266.29 **AS-3 RBC LR IRR LOW VOL 1266.29 **AS3 RBC LR LOW VOL 804.77 **AS-5 RBC 1566.28 **AS-5 RBC LR 2062.41 **ASCA IGA 69.23 **ASCA IGG 69.23 **ASCARIS IGG TO IBT 70.66 **ASPARTATE AMINOTRANSFERASE 405.27 **ASPERGILLUS AMSTELODAMNI/GLAUCUS IGE 69.23 **ASPERGILLUS ANTIGEN 183.16 **ASPERGILLUS FLAVUS ANTIBODY 124.48 **ASPERGILLUS FLAVUS IGE 69.23 **ASPERGILLUS FUMIGATUS ANTIBODY 124.48 **ASPERGILLUS IGG AB 63.46 **ASPERGILLUS NIDULANS IGE 69.23 **ASPERGILLUS NIGER ANTIBODY 124.48 **ASPERGILLUS TERREUS IGE 69.23 **ASPERGILLUS VERSICOLOR IGE 69.23 **ASPIRIN RESISTANCE 11DH THROMBOXANE B2 169.82 **ASSAY OF ALBUMIN FOR TESTOSTERONE F/W 67.78 **ASSAY OF APOLIPOPROTEIN 59.14 **ASSAY OF CHOLESTEROL (REF LAB) 60.57 **ASSAY OF LIPOPROTEIN 76.71 **ASSAY OF LIPOPROTEIN FOR PHENOTYPE 199.03 **ASSAY OF LIPOPROTEIN, ELECTROPHORESIS 154.3 **ASSAY OF TOTAL TESTOSTERONE FOR F/W 353.35 **ASSAY OF TRIGLYCERIDE (REF LAB) 79.32 **ASSAY, NOENDOCRINE RECEPTOR 499.02 **ATHENA FLUORESCENT AB EACH 462.24 **ATHENA IMMUNOASSAY NONANTIBODY 622.3 **ATHENA PROTEIN, WESTERN BLOT 622.3 **ATHENA RADIOIMMUNOASSAY NONANTIBODY 622.3 **ATHENA WESTERN BLOT 622.3 **ATOPOBIUM VAGINAE PCR 471.76 **ATTRZ TTR GENE 1764.41 **AUTO RBC 1566.28 **AUTO WHOLE BLOOD 2278.74 **AUTOANTIBODIES 245.18 **AUTOMATED HEMOGRAM 92.5 **B CELLS (CD19) 186.06 **b MELANOCYTE STIMULATING HORMONE 184.61 **B. HENSELAE IGG TITER 79.32 **B. QUINTANA IGG TITER 79.32 **BABESIA DNA BY PCR 478.82 **BABESIA MICROTI IGG 79.32 **BABESIA MICROTI IGM 79.32 **BABESIA TITER IMUGEN 79.32 **BACLOFEN SERUM 246.62 **BACTERIAL AB EACH 79.32 **BACTERIAL VAGINOSIS VP3 548.05 **BARBITURATE SCREEN 188.93 **BARBITURATES CONFIRMATION BY GCMS 252.39 **BARTONELLA HENSELAE IGM 202.74 **BARTONELLA QUINTANA IGM 202.74 **BATH SALTS BLOOD 364.89 **BATH SALTS URINE 236.52 **BCR PACKED RBC 1023.99 **BCR/ABL1 0 CHARGE FOR CML 0 **BCR-ABLE PCR 0 **BENZENE BLOOD 204.8 **BENZODIAZEPINE CONFIRMATION BY GCMS 252.39 **BENZODIAZEPINE QNT 252.39 **BENZTROPINE/COGENTINE LEVEL 187.49 **BETA GALACTOSIDASE TO MAYO 640.35 **BETA-2-MICROGLOB -UR 220.67 **BETHESDA UNITS 151.44 **BICARBONATE URINE ARUP 67.78 **BILE ACIDS FRACTIONATED 246.62 **BILE ACIDS URINE 193.26 **BILE ACIDS, URINE 246.62 **BIOAVAILABLE TESTOSTERONE (7095) 347.58 **BIOTINIDASE 157.13 **BISMUTH SERUM 299.99 **BK POLYOMA VIRUS DNA QUANT BY PCR 584.1 **BK VIRUS DNA BY PCR QUAL 478.82 **BLASTOMYCES MYCELIAL ANTIBODY BY CF 79.32 **BLASTOMYCES YEAST AB BY CF 79.32 **BLOOM DISEASE , NY 208.05 **BORDETELLA IGA AB BY FHA 227.45 **BORDETELLA IGA AB BY PT 227.45 **BORDETELLA IGG FHA AB 227.45 **BORDETELLA IGM AB BY FHA 79.32 **BORDETELLA IGM AB BY PT 79.32 **BORDETELLA PERTUSSIS 90.86 **BORRELIA HERMSII AB IGG 181.73 **BORRELIA HERMSII AB IGM 181.73 **BORRELIA MIYAMOTOI AB IGG 142.03 **BORRELIA MIYAMOTOI AB IGM 142.03 **BORRELIA MIYAMOTOI AMP PCR 469.17 **BRAF MUTATION ANALYSIS 666.32 **BREATH HYDROGEN/METHANE TEST GENOVA 385.2 **BRIVARACETAM LEVEL 187.49 **BROMIDE QUANTITATIVE 116.61 **BRUCELLA AB AGGLUTINATION 79.32 **BRUCELLA IGG AGGLUTINATION 79.32 **BRUCELLA SCREEN 79.32 **BUFFY COAT WBC CNT 51.92 **BUPROPION 187.49 **C REACTIVE PROTEIN IBD 61.52 **C. DIFF ANTIGEN 119.7 **C. DIFFICILE BY PCR 469.17 **C.IMMITIS, DNA DIRECT 274.03 **C1Q COMPLEMENT FUNCTIONAL 164.42 **C2 COMPLEMENT COMPONENT 164.42 **C3A DESARG FRAGMENT 182.51 **C3A LEVEL 164.42 **C4 BINDING PROTEIN 191.82 **C4A LEVEL 164.42 **C4A LEVEL 164.42 **C5 FUNCTIONAL 164.42 **C6 AB REFLEX TO IGG/IGM 233.66 **C6 BORRELIA 233.66 **C6 BORRELIA AB (ARUP) 363.44 **C6 FUNCTIONAL 164.42 **CAFFEINE LEVEL 177.41 **CAH PANEL11, URINE, RANDOM 905.73 **CAH(21-HYDOXYLASE DEFF) COMMON MUTATIO 533.2 **CALCOFLUOR FUNGAL STAIN 59.14 **CALPROTECTIN 177.41 **CALRETICULIN MUTATION ANALYSIS 1146.09 **CAMPYLOBACTER SPECIES AG, EIA 104.01 **CAMPYLOBACTERIA JEJUNI AB 96.93 **CANAVAN DISEASE MUT.
Load more

Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Comparative Evaluation of Isavuconazonium Sulfate
    Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 https://doi.org/10.1186/s12941-019-0311-3 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center Edward T. Van Matre1 , Shelby L. Evans2, Scott W. Mueller3, Robert MacLaren3, Douglas N. Fish3 and Tyree H. Kiser3,4* Abstract Background: Invasive fungal infections are a major cause of morbidity and mortality. Newer antifungals may provide similar efcacy with improved safety compared to older more established treatments. This study aimed to compare clinically relevant safety and efcacy outcomes in real world patients treated with isavuconazole, voriconazole, or posaconazole. Methods: This single center retrospective matched cohort study evaluated adults between January 2015 and Decem- ber 2017. The primary outcome was a composite safety analysis of antifungal related QTc prolongation, elevated liver function tests (> 5 times ULN), or any documented adverse drug event. Key secondary outcomes included: individual safety events, 30-day readmissions, magnitude of drug interactions with immunosuppressive therapy, and overall cost. Results: A total of 100 patients were included: 34 patients in the voriconazole group and 33 patients within each of the isavuconazole and posaconazole groups. The composite safety outcome occurred in 40% of the total cohort and was diferent between isavuconazole (24.2%), voriconazole (55.9%), and posaconazole (39.4%; p 0.028). Change in QTc (p < 0.01) and magnitude of immunosuppression dose reduction (p 0.029) were diferent between= the three groups. No diferences in mortality, length of stay, readmission, or infection= recurrence were observed between groups (p > 0.05 for all).
    [Show full text]
  • Antifungals, Oral
    Antifungals, Oral Therapeutic Class Review (TCR) July 13, 2018 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. July 2018 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2018 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer FDA-Approved Indication(s) for oral use clotrimazole generic .
    [Show full text]
  • ASTELLAS Factsheet 1.Pdf
    Astellas is actively committed to the infectious disease field. Our infectious disease portfolio includes three classes of drugs: AmBisome® (amphotericin B) liposome for injection, CRESEMBA® (isavuconazonium sulfate), and MYCAMINE® (micafungin sodium) for injection. We continue to expand the knowledge base of this therapeutic area and empower physicians to make evidence-based clinical decisions. Our proud history of collaborating with clinical investigators has provided opportunities around the world to study compounds that have the potential to be significant breakthroughs and allows us to generate and publish key information about these advances. In fact, Astellas pioneered the empiric antifungal clinical trial and has performed some of the world’s largest clinical trials in fungal infections. AmBisome® is indicated for the following: • The incidence of some common adverse events was • Empirical therapy for presumed fungal infection in greater in patients taking AmBisome compared to febrile neutropenic patients patients taking Abelcet in the clinical study noted above • Treatment of Cryptococcal Meningitis in HIV-infected including: chest pain, hypocalcemia, hypomagnesemia, patients confusion, headache, and rash • Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to Important Safety Information amphotericin B deoxycholate, or in patients where renal Despite significantly less nephrotoxicity observed at a dose impairment or unacceptable toxicity precludes the use range of 1.5–6.0 mg/kg/day compared to amphotericin B of amphotericin B deoxycholate deoxycholate at a dose range of 0.3–1.2 mg/kg/day in a • Treatment of visceral leishmaniasis; in randomized clinical trial, dose-limiting renal toxicity may still immunocompromised patients with visceral be observed with AmBisome.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Serum Uric Acid Control for Prevention of Gout Flare in Patients with Asymptomatic Hyperuricaemia: a Retrospective Cohort Study
    Inflammatory arthritis Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-220439 on 22 June 2021. Downloaded from EPIDEMIOLOGICAL SCIENCE Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check- up data in Japan Ruriko Koto ,1 Akihiro Nakajima,2 Hideki Horiuchi,1 Hisashi Yamanaka3,4,5 Handling editor Josef S ABSTRACT Key messages Smolen Objectives In patients with gout, treating to target serum uric acid levels (sUA) of ≤6.0 mg/dL is universally ► Additional supplemental What is already known about this subject? material is published online recommended to prevent gout flare. However, there is ► For adequate management of gout, guidelines only. To view, please visit the no consensus on asymptomatic hyperuricaemia. Using around the world consistently recommend the journal online (http:// dx. doi. Japanese health insurance claims data, we explored use of urate- lowering therapy (ULT) to maintain org/ 10. 1136/ annrheumdis- potential benefits of sUA control for preventing gout 2021- 220439). serum uric acid levels (sUA) of ≤ 6.0 mg/dL. flare in subjects with asymptomatic hyperuricaemia. 1 Methods This retrospective cohort study analysed the Medical Science Department, What does this study add? Teijin Pharma Limited, Chiyoda- JMDC Claims Database from April 2012 through June In both patients population with asymptomatic ku, Tokyo, Japan 2019. Subjects with sUA ≥8.0 mg/dL were identified, and ► 2Pharmaceutical Development hyperuricaemia and those with gout, our disease status (prescriptions for urate-lowering therapy Administration Department, study indicates that the occurrence of gout (ULT), occurrence of gout flare, sUA) was investigated for Teijin Pharma Limited, Chiyoda- flare can be lowered by using ULT to maintain ku, Tokyo, Japan 1 year.
    [Show full text]
  • Isavuconazonium
    Drug and Biologic Coverage Criteria Effective Date ............................................ 8/1/2020 Next Review Date… ..................................... 8/1/2021 Coverage Policy Number ................................ P0011 Isavuconazonium Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 Background .......................................................... 2 References .......................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the
    [Show full text]
  • 207500S005,207501S004lbl.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Infusion-related reactions were reported during intravenous These highlights do not include all the information needed to use administration of CRESEMBA. Discontinue the infusion if these CRESEMBA® safely and effectively. See full prescribing information for reactions occur. (5.2) CRESEMBA®. • Hypersensitivity Reactions: Serious hypersensitivity and severe skin CRESEMBA® (isavuconazonium sulfate) capsules, for oral use reactions, such as anaphylaxis or Stevens Johnson syndrome, have been CRESEMBA® (isavuconazonium sulfate) for injection, for intravenous reported during treatment with other azole antifungal agents. use Discontinue CRESEMBA for exfoliative cutaneous reactions. (5.3) Initial U.S. Approval: 2015 • Embryo-Fetal Toxicity: CRESEMBA may cause fetal harm when ------------------------RECENT MAJOR CHANGES----------------------------­ administered to a pregnant woman. Advise pregnant women of the Warnings and Precautions, Embryo-Fetal Toxicity (5.4) 11/2019 potential risk to the fetus. Advise females of reproductive potential to ---------------------------INDICATIONS AND USAGE---------------------------­ use an effective method of contraception. (5.4, 8.1, 8.3) CRESEMBA® is an azole antifungal indicated for use in the treatment of: • Drug Interactions: Review patient’s concomitant medications. Several • Invasive aspergillosis. (1.1) drugs may significantly alter isavuconazole concentrations. Isavuconazole may alter concentrations of several drugs. (5.5, 7, 12.3) • Invasive mucormycosis. (1.2)
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
    Top Curr Chem (Z) (2018) 376:5 https://doi.org/10.1007/s41061-018-0184-5 REVIEW Analysis of US FDA‑Approved Drugs Containing Sulfur Atoms Kevin A. Scott1,2 · Jon T. Njardarson1 Received: 20 November 2017 / Accepted: 5 January 2018 / Published online: 22 January 2018 © Springer International Publishing AG, part of Springer Nature 2018 Abstract In this review, we discuss all sulfur-containing FDA-approved drugs and their structures. The second section of the review is dedicated to structural analy- sis and is divided into 14 subsections, each focusing on one type of sulfur-contain- ing moiety. A concise graphical representation of each class features drugs that are organized on the basis of structural similarity, evolutionary relevance, and medical indication. This review ofers a unique and comprehensive overview of the struc- tural features of all sulfur-containing FDA-approved drugs to date. Keywords Sulfonamide · Thioether · Sulfoxide · Sulfone · Sulfate · Sulfur heterocycle Abbreviations 6-APA 6-Aminopenicillanic acid ADP Adenosine diphosphate cGMP Cyclic guanosine monophosphate COX-2 Cyclooxygenase-2 GERD Gastroesophageal refux disease GPCR G protein-coupled receptor HIV Human immunodefciency virus mRNA Messenger RNA NSAID Nonsteroidal anti-infammatory drugs SMN1 Survival motor neuron 1 This article is part of the Topical Collection “Sulfur Chemistry”, edited by Xuefeng Jiang. * Jon T. Njardarson [email protected] 1 Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA 2 Department of Pharmacology
    [Show full text]
  • CRESEMBA (Isavuconazonium Sulfate) Is the Prodrug of Isavuconazole, an Azole Antifungal Drug
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Infusion-related reactions were reported during intravenous administration These highlights do not include all the information needed to use of CRESEMBA. Discontinue the infusion if these reactions occur. (5.2) CRESEMBA® safely and effectively. See full prescribing information for • Hypersensitivity Reactions: Anaphylactic reactions, with fatal outcome, CRESEMBA®. have been reported during treatment with CRESEMBA. Discontinue CRESEMBA if a patient experiences an anaphylactic reaction. Serious CRESEMBA® (isavuconazonium sulfate) capsules, for oral use hypersensitivity and severe skin reactions, such as anaphylaxis or Stevens- CRESEMBA® (isavuconazonium sulfate) for injection, for intravenous Johnson syndrome, have been reported during treatment with other azole use antifungal agents. Discontinue CRESEMBA for exfoliative cutaneous Initial U.S. Approval: 2015 reactions. (5.3) • Embryo-Fetal Toxicity: CRESEMBA may cause fetal harm when -------------------------- RECENT MAJOR CHANGES -------------------------- administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use Dosage and Administration, Preparation Instructions for the Nasogastric Tube an effective method of contraception. (5.4, 8.1, 8.3) Administration of the Injection Formulation (2.5) 04/2021 • Drug Interactions: Review patient’s concomitant medications. Several drugs may significantly alter isavuconazole concentrations. Isavuconazole Warnings and Precautions,
    [Show full text]